The MIC regimen in non-small cell lung cancer
| Autor: | M.H. Cullen |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology Cancer Research medicine.medical_specialty Chemotherapy Ifosfamide Performance status business.industry Standard treatment medicine.medical_treatment Phases of clinical research medicine.disease Chemotherapy regimen Surgery Regimen Internal medicine medicine Lung cancer business medicine.drug |
| Zdroj: | Lung Cancer. 9:81-89 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/0169-5002(93)90173-u |
| Popis: | The three most active single agents against non-small cell lung cancer (NSCLC) are mitomycin, ifosfamide, and cisplatin, which have been associated with response rates of 20, 26 and 20%, respectively. A Phase II study was therefore commenced to evaluate a combination of the three drugs (MIC) in patients with inoperable, histologically confirmed NSCLC. The 56% overall and 11% complete response rates established in that trial suggest that MIC is among the most active chemotherapy regimens evaluated for NSCLC with some improvement in performance status and weight in responding patients. Larger-scale randomized trials of MIC are currently under way and, preliminary response data support the results of earlier studies. The ultimate role for chemotherapy in NSCLC will depend upon its impact on survival and quality of life. As yet neither have been evaluated thoroughly enough for any chemotherapy regimen to be regarded as standard treatment in this disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|